Format

Send to

Choose Destination
Clin Infect Dis. 2007 Oct 15;45(8):1019-24. Epub 2007 Sep 11.

Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation.

Author information

1
Hematologie-Greffe, Université Paris 7, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.

Abstract

Among 40 allogeneic stem cell transplant recipients who developed symptomatic respiratory syncytial virus infection, including 22 patients with lower respiratory tract infection, 19 received palivizumab (9 of whom had upper respiratory tract disease). Palivizumab did not prevent progression to lower respiratory infection and had no impact on the overall survival rate.

PMID:
17879919
DOI:
10.1086/521912
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center